BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38051455)

  • 21. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis.
    Jiang J; Zhao C; Zhang F; Liu Z; Zhou K; Ren X; Wan Y
    BMJ Open; 2022 Sep; 12(9):e060782. PubMed ID: 36123063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
    Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
    Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L
    J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer.
    Hong X; Chen Q; Ding L; Liang Y; Zhou N; Fang W; Chen X; Wu H
    Oncotarget; 2017 Jun; 8(25):41631-41640. PubMed ID: 28427213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
    Christopoulos P; Bozorgmehr F; Brückner L; Chung I; Krisam J; Schneider MA; Stenzinger A; Eickhoff R; Mueller DW; Thomas M
    BMC Cancer; 2021 Jun; 21(1):743. PubMed ID: 34182952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study.
    Yang G; Ma D; Xu H; Yang L; Li J; Xing P; Hao X; Wang Y
    Cancer Med; 2019 Oct; 8(13):5823-5830. PubMed ID: 31407528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases.
    Xing P; Wang S; Hao X; Zhang T; Li J
    Oncotarget; 2016 Dec; 7(51):84666-84674. PubMed ID: 27835868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.
    Zou Z; Hao X; Zhang C; Li H; Dong G; Peng Y; Ma K; Guo Y; Shan L; Zhang Y; Liang L; Gu Y; Xing P; Li J
    Thorac Cancer; 2022 Jan; 13(1):107-116. PubMed ID: 34851035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
    Johung KL; Yeh N; Desai NB; Williams TM; Lautenschlaeger T; Arvold ND; Ning MS; Attia A; Lovly CM; Goldberg S; Beal K; Yu JB; Kavanagh BD; Chiang VL; Camidge DR; Contessa JN
    J Clin Oncol; 2016 Jan; 34(2):123-9. PubMed ID: 26438117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.
    Miloš P; Jana S; Vítězslav K; Monika Š; Leona K; Jaromír R; Renata C; Markéta Č; Andrea B; Juraj K; Michal H; Milada Z; Marek K; Helena Č; Martin S
    Klin Onkol; 2018; 31(3):207-212. PubMed ID: 30441974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
    Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?
    Wrona A
    Cancer Radiother; 2019 Sep; 23(5):432-438. PubMed ID: 31331844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study.
    Zou Z; Xing P; Hao X; Wang Y; Song X; Shan L; Zhang C; Liu Z; Ma K; Dong G; Li J
    BMC Med; 2022 Jan; 20(1):12. PubMed ID: 35039026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM
    Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer.
    Ganti AK; Lin CW; Yang E; Wong WB; Ogale S
    J Manag Care Spec Pharm; 2022 Mar; 28(3):305-314. PubMed ID: 34913728
    [No Abstract]   [Full Text] [Related]  

  • 36. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).
    Aguado de la Rosa C; Cruz Castellanos P; Lázaro-Quintela M; Dómine M; Vázquez Estévez S; López-Vivanco G; Fírvida Pérez JL; Alonso Romero JL; Ferrera Delgado L; García Girón C; Diz Taín P; Álvarez Álvarez R; Mut Sanchís P; Fernández Cantón I; Manrique Abós I; Martínez Aguillo M; Gómez-Aldaraví Gutiérrez L; Ortega Granados AL; Álvarez Cabellos R; García Sebastián A; García Sifuentes LF; Reguart N
    Lung Cancer; 2022 Nov; 173():83-93. PubMed ID: 36162227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control.
    Huang SH; Huang AC; Wang CC; Chang WC; Liu CY; Pavlidis S; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
    Thorac Cancer; 2019 Dec; 10(12):2274-2281. PubMed ID: 31613427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Canadian perspectives: update on inhibition of
    Melosky B; Cheema P; Agulnik J; Albadine R; Bebb DG; Blais N; Burkes R; Butts C; Card PB; Chan AMY; Hirsh V; Ionescu DN; Juergens R; Morzycki W; Poonja Z; Sangha R; Tehfe M; Tsao MS; Vincent M; Xu Z; Liu G
    Curr Oncol; 2018 Oct; 25(5):317-328. PubMed ID: 30464681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
    Horn L; Wang Z; Wu G; Poddubskaya E; Mok T; Reck M; Wakelee H; Chiappori AA; Lee DH; Breder V; Orlov S; Cicin I; Cheng Y; Liu Y; Fan Y; Whisenant JG; Zhou Y; Oertel V; Harrow K; Liang C; Mao L; Selvaggi G; Wu YL
    JAMA Oncol; 2021 Nov; 7(11):1617-1625. PubMed ID: 34473194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.
    Hizal M; Bilgin B; Paksoy N; Kılıçkap S; Atcı MM; Kahraman S; Keskinkılıç M; Bilgetekin İ; Ayhan M; Tural D; Eren Ö; Akkoç Mustafayev FN; Yaman Ş; Tatlı AM; Bayram E; Kutlu Y; Ertürk İ; Özcan E; Gülmez A; Korkmaz M; Akagündüz B; Erdem D; Telli TA; Aksoy A; Üskent N; İriağaç Y; Baytemür NK; Aydın D; Şakalar T; Arak H; Selçukbiricik F; Ergün Y; Korkmaz T; Ak N; Ünal Ç; Akdeniz N; Özgün MA; Öksüzoğlu B; Yalçın B; Öztop İ; Algın E; Sakin A; Aydıner A; Yumuk PF; Şendur MAN
    Future Oncol; 2022 Jul; 18(23):2573-2582. PubMed ID: 35734870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.